Cited by 54Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsAutophagy in Disease and Therapy

BHLHE40/41 regulate Microglia and Peripheral Macrophage Responses Associated With Alzheimer's Disease and Other Disorders of Lipid‐rich Tissues

Open access
Podleśny-Drabiniok, Anna, Novikova, Gloriia, Liu, Yiyuan, Dunst, Josefine, Temizer, Rose, Giannarelli, Chiara, Marro, Samuele, Kreslavsky, Taras +2 more·2024·Nature Communications

Abstract

Genetic and experimental evidence suggests that Alzheimer’s disease (AD) risk alleles and genes may influence disease susceptibility by altering the transcriptional and cellular responses of macrophages, including microglia, to damage of lipid-rich tissues like the brain. Recently, sc/nRNA sequencing studies identified similar transcriptional activation states in subpopulations of macrophages in aging and degenerating brains and in other diseased lipid-rich tissues. We collectively refer to these subpopulations of microglia and peripheral macrophages as DLAMs. Using macrophage sc/nRNA-seq data from healthy and diseased human and mouse lipid-rich tissues, we reconstructed gene regulatory networks and identified 11 strong candidate transcriptional regulators of the DLAM response across species. Loss or reduction of two of these transcription factors, BHLHE40/41, in iPSC-derived microglia and human THP-1 macrophages as well as loss of Bhlhe40/41 in mouse microglia, resulted in increased expression of DLAM genes involved in cholesterol clearance and lysosomal processing, increased cholesterol efflux and storage, and increased lysosomal mass and degradative capacity. These findings provide targets for therapeutic modulation of macrophage/microglial function in AD and other disorders affecting lipid-rich tissues.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-46315-7

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • BHLHE40/41 regulate genes involved in lipid clearance (ABCA1, APOE, LPL), lysosomal processing (CTSD, PSAP, LAMP-1 and -2), TREM2, metabolism (PPARγ, LXR), and efferocytosis.

    “Specifically, BHLHE40/41 regulate genes involved in lipid clearance (ABCA1, APOE, LPL), lysosomal processing (CTSD, PSAP, LAMP‐ 1 and ‐2), TREM2, metabolism (PPARγ, LXR), and efferocytosis (the process by which apoptotic cells are cleared by phagocytic cells) [53].”

    From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [53]

    The Results report that loss of BHLHE40/41 increased expression of genes involved in cholesterol clearance and lysosomal processing in human iPSC-derived microglia; Fig. 5 specifically identifies APOE and ABCA1. The Discussion describes opposition to LXR:RXR-regulated pathways. Our copy does not establish BHLHE40/41 regulation of every gene listed—particularly LPL, CTSD, PSAP, LAMP-1/2, and TREM2—or of efferocytosis; it discusses efferocytosis in other contexts. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • BHLHE40/41 bind to open chromatin at promoters and enhancers of LXR:RXR and MiT/TFE family transcriptional factors, acting as transcriptional repressors and modulating cholesterol/lipid efflux genes and lysosomal genes, thereby influencing cellular clearance functions.

    “BHLHE40/41 bind to open chromatin at promoters and enhancers of LXR:RXR and MiT/TFE family transcriptional factors, acting as transcriptional repressors and modulating cholesterol/lipid efflux genes and lysosomal genes, thereby influencing cellular clearance functions (Figure 1 and Table 2) [53, 54].”

    From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [53]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • PU.1, IRF8, and BHLHE40/41 regulate multiple downstream targets that orchestrate microglial immune response functions, including phagocytosis, cytokine production, and inflammatory signaling.

    “PU.1, IRF8, and BHLHE40/41 regulates multiple downstream targets that orchestrate microglial immune response functions, including phagocytosis, cytokine production, and inflammatory signaling”

    From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [53]

    The Results section on DLAM gene promoters identifies BHLHE41 and SPI1/PU.1 regulons enriched for likely direct targets. Other Results sections link BHLHE40/41 knockout in human iPSC-derived microglia to predicted changes in cell engulfment and measured changes in cytokine secretion. The paper’s shortlist of candidate regulators does not include IRF8, and these passages do not establish the claimed downstream regulation by all three factors or specifically demonstrate inflammatory signaling. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • MEF2C functions as a counterbalance by suppressing excessive pro-inflammatory responses.

    “MEF2C functions as a counterbalance by suppressing excessive pro‐inflammatory responses”

    From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [53]

    The Results section on candidate DLAM transcription factors names MEF2C as a candidate regulator of macrophage and microglial responses (page unavailable). It does not say that MEF2C suppresses excessive pro-inflammatory responses; the Results passage on reduced pro-inflammatory cytokines concerns BHLHE40/41 knockout, not MEF2C. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 101 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. [86]Obradovic, A. et al. PISCES: a pipeline for the systematic, protein activity-based analysis of single-cell RNA sequencing data. bioRxiv 2021.05.20.445002. Preprint at 10.1101/2021.05.20.445002 (2021). · DOI
  2. [92]Andrews, S. & Others. FastQC: a quality control tool for high throughput sequence data. Preprint at (2010).

Cited by

Sorted by citations

Authors
Podleśny-Drabiniok, A., Novikova, G., Liu, Y., Dunst, J., Temizer, R., Giannarelli, C., Marro, S., Kreslavsky, T., Marcora, E., & Goate, A. M.
Affiliations
  • Genentech (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Karolinska University Hospital (SE)
  • New York University (US)
Corresponding author
  • Marcora, Edoardo
  • Goate, Alison Mary
Venue
Nature Communications
Published
2024-03-06
Volume
15
Issue
1
Pages
2058-2058
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4392503471
Cited by
52
References
101
Citations by year
2026: 25 · 2025: 18 · 2024: 9
FWCI
8.11
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • American Heart Association (20SFRN35210252)
  • New York State Department of Health (NYSTEM-C32561GG)
  • BrightFocus Foundation (A2021014F)
  • JPB Foundation (U01AG058635)
  • New York State Stem Cell Science (NYSTEM‐C32561GG, C32561GG)
  • Graduate Women in Science
  • Georgia Clinical and Translational Science Alliance (UL1TR004419)
  • National Institutes of Health (1r56ag081417-01, 1s10od026880-01, 1s10od030463-01, UL1TR004419)
  • National Institute on Aging (U01AG058635, U01AG066757, R56 AG081417, RF1AG054011, P30AG066514)
  • National Heart, Lung, and Blood Institute (R01HL153712)
  • National Center for Advancing Translational Sciences (S10OD026880, S10OD030463)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
Keywords
microglia, peripheral macrophages, Alzheimer's disease, gene regulatory networks, cholesterol efflux, lysosomal function, macrophage heterogeneity, iPSC-derived microglia, THP-1 macrophages, transcription factors
MeSH terms
Alzheimer Disease, Animals, Cholesterol, Humans, Lipids, Macrophages, Microglia, Homeodomain Proteins, Mice, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review